Why Big Pharma is turning its back on R&D

06/16/2010 | Reuters

Some of the world's biggest pharmaceutical companies are cutting back on their research programs as their most lucrative patents near expiration. With generics likely to wipe out billions of dollars in revenue, the companies are increasingly buying up predesigned drugs from outside suppliers, effectively moving from the research business into the drug-distribution business. "Science really doesn't pay any more," says one young researcher.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Business

Job Title Company Location
Vice President, HEDIS & Performance Outcomes
Dayton, OH
Pharmacy Benefit Analyst/ Auditor
Nationwide, SL_Nationwide
Vice President, Girls and Women Strategy
United Nations Foundation
Washington, DC